文献类型：期刊文献

中文题名：右佐匹克隆治疗慢性失眠患者的临床疗效及安全性

英文题名：Clinical efficacy and safety of eszopiclone in treatment of patients with chronic insomnia

作者：赵剑华[1];张静霞[1];刘敏科[2]

第一作者：赵剑华

机构：[1]甘肃中医药大学附属医院脑病科;[2]甘肃中医药大学附属医院神经内科

第一机构：甘肃中医药大学第二附属医院

年份：2019

卷号：0

期号：5

起止页码：288

中文期刊名：中国新药与临床杂志

外文期刊名：Chinese Journal of New Drugs and Clinical Remedies

收录：CSTPCD;;北大核心:【北大核心2017】；CSCD:【CSCD_E2019_2020】；

基金：甘肃省自然科学基金项目(145RJZA184

语种：中文

中文关键词：右佐匹克隆;失眠症;治疗结果;安全;慢性失眠

外文关键词：eszopiclone;insomnia;treatment outcome;safety;chronic insomnia

摘要：目的研究右佐匹克隆治疗慢性失眠患者的临床疗效及安全性。方法选取原发性慢性失眠患者80例,随机分为治疗组和对照组各40例。治疗组给予右佐匹克隆3 mg,睡前口服,对照组给予同等样式的安慰剂,治疗时间为8周。比较两组治疗前和治疗第2、 4、 8周末匹兹堡睡眠质量指数(PSQI)、汉密尔顿抑郁量表(HAMD)评分。观察和比较两组不良反应发生情况。结果对照组治疗后PSQI和HAMD评分有下降趋势,但与治疗前比较无显著差异(P> 0.05),治疗组在治疗第4、 8周末PSQI、HAMD评分明显降低(P <0.05, P <0.01),且与对照组有显著差异(P <0.05, P <0.01)。两组不良反应发生率无显著差异(P> 0.05)。结论右佐匹克隆治疗慢性失眠患者疗效显著,可改善患者的焦虑、抑郁情绪,且安全性较高。
AIM To study the clinical efficacy and safety of eszopiclone in the treatment of patients with chronic insomnia.METHODS Eighty patients with primary chronic insomnia were randomly divided into treatment group and control group(n=40 for each).The treatment group received eszopiclone at a dose of 3 mg before going to bed for 8 weeks,and the control group received an equivalent oral placebo.Pittsburgh Sleep Quality Index Scale(PSQI)and Hamilton Depression Rating Scale(HAMD)scores were compared between the two groups before the treatment and at the 2 nd,4 th and 8 th weekend of treatment respectively.Incidence of adverse drug reactions were observed and compared between the two groups.RESULTS The PSQI and HAMD scores of the control group had a downward trend after the treatment,but there was no significant difference compared with those before treatment(P>0.05).The PSQI and HAMD scores in the treatment group were decreased significantly at the end of the 4 th and 8 th week of the treatment(P<0.05,P<0.01),and there was a significant difference between the treatment group and the control group(P<0.05,P<0.01).There was no statistical difference in the incidence of adverse reactions between the two groups(P>0.05).CONCLUSION Eszopiclone has a significant effect on patients with chronic insomnia.It can improve the anxiety and depression of the patients safely.